3rd Quarter - Report
LINDE INC. for LINDE INC., LINDE, PLC AND OTHER ENTITIES RELATED TO LINDE, PLC
Firm
Income
—
Expenses
$270,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Energy R&D funding; General international tax issues affecting U.S. based multinational corporations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| VALERIE KING | — |
| SCOTT RUMMANS | — |
Medicare/Medicaid MMM
Monitoring healthcare issues in House and Senate; S.882, Drug and Device Accountability Act of 2009. HR 3200, The America's Affordable Health Choices Act of 2009.
| Lobbyist | Covered position, as disclosed |
|---|---|
| VALERIE KING | — |
| SCOTT RUMMANS | — |
Trade (domestic/foreign) TRD
General U.S. - Canada trade issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| VALERIE KING | — |
Environment/Superfund ENV
American Clean Energy and Security Act of 2009 (ACES)
| Lobbyist | Covered position, as disclosed |
|---|---|
| VALERIE KING | — |
| SCOTT RUMMANS | — |
Energy/Nuclear ENG
Energy R&D funding; increase and specify FUSRAP funding for the former Linde/Air Products site.
| Lobbyist | Covered position, as disclosed |
|---|---|
| VALERIE KING | — |
| SCOTT RUMMANS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.